Skip to content
← Full study record

NCT05256381 · MORE INFO

Limitations, agreements, and source contact

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors · Source last updated 2025-11-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The results of this clinical trial will be published and/or presented at scientific meetings in their totality in a timely manner. Any formal publication of clinical trial results will be a collaborative effort between the sponsor and the investigator(s). All manuscripts or abstracts will be reviewed and approved in written by the sponsor before submission. The sponsor may request a delay in publication if there are important intellectual property concerns.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
kapsa@sotio.com
organization
SOTIO Biotech a.s.
phone
(+420) 2241 74448
title
Richard Kapsa
Complete source fields
certain Agreement
other Details
The results of this clinical trial will be published and/or presented at scientific meetings in their totality in a timely manner. Any formal publication of clinical trial results will be a collaborative effort between the sponsor and the investigator(s). All manuscripts or abstracts will be reviewed and approved in written by the sponsor before submission. The sponsor may request a delay in publication if there are important intellectual property concerns.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
kapsa@sotio.com
organization
SOTIO Biotech a.s.
phone
(+420) 2241 74448
title
Richard Kapsa

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice